格隆汇12月14日丨昊海生科(688366.SH)发布公告，赵明璟已辞任联席公司秘书、授权代表及法律程序 代理人，自2025年12月12日起生效。黎映彤已获委任为联席公司秘书、授权代表及法律程序代理人，自 同日起生效。 ...

格隆汇12月14日丨昊海生科(688366.SH)发布公告，赵明璟已辞任联席公司秘书、授权代表及法律程序 代理人，自2025年12月12日起生效。黎映彤已获委任为联席公司秘书、授权代表及法律程序代理人，自 同日起生效。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 上海昊海生物科技股份有限公司（於中華人民共和國註冊成立的股份有限公司） 呈交日期： 2025年12月12日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 H | | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 06826 | 說明 H 股 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | | 事件 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容所產生或因依 賴該等內容而引致的任何損失承擔任何責任。 Shanghai Haohai Biological Technology Co., Ltd.* 上海昊海生物科技股份有限公司（「本公司」）董事會（「董事會」）謹此宣佈，趙明 璟先生（「趙先生」）已辭任(i)本公司其中一位聯席公司秘書（「聯席公司秘書」）； (ii)根據香港聯合交易所有限公司（「聯交所」）證券上市規則（「上市規則」）第3.05 條所規定的本公司之授權代表（「授權代表」）；及(iii)根據上市規則第19A.13(2)條 及公司條例（香港法例第622章）第16部所規定的代本公司於香港接受法律程序送 達文件及通知書的本公司之授權代表（「法律程序代理人」），自2025年12月12日起 生效。 趙先生確認彼與董事會並無任何意見分歧，亦無有關其不再擔任上述本公司職位 之其他事宜需提請本公司股東及聯交所垂注。 上海昊海生物科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：682 ...

Core Viewpoint - The company Haohai Biological Technology (688366.SH) plans to acquire a 19.8% stake in Jiangxi Ruiji Biological Engineering Technology Co., Ltd. for RMB 38.35 million, enhancing its presence in the high-value medical device sector focused on biological amniotic membranes [1] Group 1: Company Acquisition - Haohai Biological Technology will use its own funds to acquire 8.4661 million shares from shareholders Miao Jiuchang and Miao Chunyu [1] - The acquisition allows Haohai to gain distribution rights for Ruiji's products within China, thereby expanding its product portfolio in the ophthalmology and orthopedics fields [1] Group 2: Business Overview of Ruiji - Ruiji Biological was established in 2002 and specializes in the production and sale of biological amniotic membranes, which are classified as Class III medical devices [1] - The main products include convex and concave amniotic membranes, biological orthopedic amniotic membranes, and wet biological amniotic membranes, used primarily in orthopedic and ophthalmic applications [1] Group 3: Strategic Implications - The acquisition is expected to provide important technical and material foundations for Haohai's research and development in regenerative medicine and tissue engineering [1] - The human-derived biological characteristics of the amniotic materials are anticipated to drive innovation and technological upgrades in subsequent product offerings [1]

Core Viewpoint - Company Haohai Biological Technology (688366.SH) plans to acquire 8.4661 million shares of Jiangxi Ruiji Biological Engineering Technology Co., Ltd. for RMB 38.3515 million, representing 19.8% of Ruiji's total share capital [1] Group 1: Company Overview - Jiangxi Ruiji was established in 2002 and specializes in the production and sales of biological amniotic membranes [1] - The main products include convex and concave amniotic membrane products, biological orthopedic amniotic membrane products, and wet biological amniotic membrane products, classified as Class III medical devices [1] Group 2: Market and Product Applications - The products are primarily used in orthopedic and ophthalmic fields, including tendon repair, treatment of ocular burns and injuries, and support after lacrimal duct obstruction [1] - The acquisition allows the company to gain distribution rights for Ruiji's products in China, entering the high-value medical device sector of biological amniotic membranes [1] Group 3: Strategic Implications - The acquisition is expected to effectively supplement the company's existing product portfolio and expand its business coverage in the ophthalmic and orthopedic sectors [1] - Ruiji's amniotic membrane materials possess human-derived biological characteristics, providing essential technical and material foundations for the company's research and development in regenerative medicine and tissue engineering [1] - This move is anticipated to drive subsequent product innovation and technological upgrades for the company [1]

Core Viewpoint - Haohai Biological Technology (688366) plans to acquire 8.4661 million shares of Jiangxi Ruiji Biological Engineering Technology Co., Ltd. for 38.3515 million yuan, representing 19.8% of Ruiji's total share capital [1] Group 1: Company Acquisition - The acquisition will be funded by the company's own capital [1] - The target company, Ruiji Biological, was established in 2002 and specializes in the production and sales of biological amniotic membranes [1] - The main products include convex and concave amniotic membrane products, biological orthopedic amniotic membrane products, and wet biological amniotic membrane products, classified as Class III medical devices [1] Group 2: Market and Product Applications - The products are primarily used in orthopedic and ophthalmic fields, including tendon repair, treatment of ocular burns and injuries, and support after lacrimal duct obstruction procedures [1] - By investing in Ruiji Biological, the company aims to gain distribution rights for Ruiji's products in China, effectively entering the high-value medical device market of biological amniotic membranes [1] - This acquisition will enhance the company's existing product portfolio and expand its business coverage in the ophthalmic and orthopedic sectors [1]

格隆汇12月12日丨昊海生科(688366.SH)公布，为有效补充公司产品组合，增强业务抗风险能力及盈利 稳定性，并为公司创新材料产品开发奠定基础，经公司第六届董事会第六次会议审议通过，公司及独立 第三方钟晓燕与瑞济生物现有股东苗九昌、苗春云签订《股份转让框架协议》，分别以人民币3835.15 万元、475.6万元的价格分三个阶段受让苗九昌、苗春云合计持有的瑞济生物846.61万股、104.99万股股 份。交易完成后，公司将持有瑞济生物19.8000%的股份。本次交易资金来源为公司自有资金，不会导 致公司合并报表范围变更。 ...

格隆汇12月12日丨昊海生科(688366.SH)公布，为有效补充公司产品组合，增强业务抗风险能力及盈利 稳定性，并为公司创新材料产品开发奠定基础，经公司第六届董事会第六次会议审议通过，公司及独立 第三方钟晓燕与瑞济生物现有股东苗九昌、苗春云签订《股份转让框架协议》，分别以人民币3835.15 万元、475.6万元的价格分三个阶段受让苗九昌、苗春云合计持有的瑞济生物846.61万股、104.99万股股 份。交易完成后，公司将持有瑞济生物19.8000%的股份。本次交易资金来源为公司自有资金，不会导 致公司合并报表范围变更。 ...

证券代码：688366 证券简称：昊海生科 公告编号：2025-050 上海昊海生物科技股份有限公司 关于购买股权暨与关联人共同投资的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 上海昊海生物科技股份有限公司（以下简称"公司"）拟以自有资金人民 币 38,351,487.36 元受让苗九昌、苗春云合计持有的江西瑞济生物工程技术股份 有限公司（以下简称"瑞济生物"）8,466,112 股股份，占瑞济生物总股本的 19.8000%（以下简称"本次交易"）。 截至本公告披露日，公司关联人游捷、唐敏捷、蔡小川分别持有瑞济生 物 21.6910%、0.7718%、0.8653%股权。本次受让股权后将形成与关联人共同投 资。本次交易未涉及与关联人之间发生资金往来或者权属转移。 本次交易未构成重大资产重组。 截至本公告披露日，包括本次交易，公司过去 12 个月与同一关联人进行 的交易或与不同关联人进行的同一交易类别下标的相关的交易金额超过 3,000 万 元，但未达到公司最近一期经审计总资产或总市值的 1%以上。 本 ...